MSK Metanolsko-Sircetni Kompleks A.D. (MSK) is a Serbian chemical producer specializing in methanol, acetic acid, and related acetyl derivatives. The company operates manufacturing assets in Serbia, supplying key basic chemicals used as feedstocks and intermediates across the chemical value chain.
MSK’s portfolio supports applications in solvents, resins, plastics, adhesives, and pharmaceuticals, serving customers in domestic and regional markets in Central and Southeast Europe.
Also known as MSKCC and Memorial Sloan-Kettering Cancer Center.
FDA grants full approval to the all‑oral imlunestrant + abemaciclib combination for adults with ER+, HER2–, ESR1‑mutated advanced or metastatic breast cancer after prior endocrine therapy.
Phase I/II ARROS‑1 data show 94% ORR, 90% progression‑free at 12 months and strong intracranial activity; supplemental US submission planned for 2026.
FDA sets PDUFA Feb 2027 for Jemperli’s supplemental filing based on AZUR‑1 data showing sustained 12‑month complete responses, potentially avoiding chemo, radiation and surgery.
FDA clears zidesamtinib for adults with advanced ROS1‑positive NSCLC after prior ROS1 inhibitor; ARROS‑1 showed 44% ORR and durable responses, including in brain metastases.
Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.
Inluriyo™ improves survival in ER+, HER2- breast cancer, both alone and with abemaciclib, extending time to chemotherapy and showing durable benefits across patient groups.
